Question explored with the scientific record
Are Covid vaccines harmful
The evidence shows COVID-19 vaccines cause real, documented harms, especially heart inflammation in young men and rare clotting disorders with adenovirus-based shots, but the same harms are more common and more severe from the infection itself.
The strongest and most consistent safety signal is myocarditis after mRNA vaccines. In young men aged 16-29, the risk after a second dose runs about 10-15 cases per 100,000, with Moderna carrying a higher risk than Pfizer [1][3][4][6]. Most cases are mild and resolve quickly, but longer-term follow-up found persistent heart abnormalities in over half of patients at three months [6]. The same meta-analyses show the risk of myocarditis from a COVID-19 infection is roughly 7 to 16 times higher than from vaccination [2][5]. The infection also produces more severe outcomes like heart failure and death [2][9].
For clotting, the adenovirus vaccines (AstraZeneca, Johnson & Johnson) caused a rare but dangerous condition called vaccine-induced immune thrombotic thrombocytopenia (VITT), with cerebral sinus vein thrombosis rates around 16 per million doses [8][10]. mRNA vaccines show no meaningful clotting risk [7][8]. Again, COVID-19 infection raises clotting risk far more: one UK study found venous thromboembolism risk was 14 times higher after infection than after the AstraZeneca vaccine [9].
| Harm | After mRNA vaccine | After COVID-19 infection |
|---|---|---|
| Myocarditis in young men | 10-15 per 100,000 doses | 7-16 times higher risk |
| Clotting disorders | Rare (mRNA); ~16/million (adenovirus) | 14 times higher than adenovirus vaccine |
The evidence base has real gaps. No long-term safety trials beyond a few months exist. The studies are mostly observational, funded by manufacturers or public health agencies with a vested interest in the outcome. Passive reporting systems like VAERS detect only a fraction of real events. But the pattern across dozens of large population studies is consistent: the vaccines cause measurable harm, and the infection causes more.
My call: COVID-19 vaccines are harmful in the sense that they cause documented adverse events, but for most people the harm from the vaccine is smaller than the harm from the infection. Confidence: moderate.
Sources used 10
-
Heart inflammation risk after COVID-19 vaccine
This study investigates the risk of myocarditis following COVID-19 vaccination, highlighting its occurrence primarily in younger males after the second dose and comparing it to the risk associated with COVID-19 infection itself.
DOI: 10.5603/CJ.a2021.0161 -
Myocarditis after COVID-19: Comparing risks from vaccination and infection
A meta-analysis and FDA reports show COVID-19 infection carries a higher risk of myocarditis and more severe outcomes than mRNA vaccination, so vaccine benefits outweigh risks.
DOI: 10.47391/jpma.32162 -
The benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditis
COVID-19 mRNA vaccination clearly outweighs the rare risk of myocarditis and pericarditis; incidence is about 1-4 per 100,000, mainly in young males after the second dose, and COVID-19 itself poses a much larger myocarditis risk.
DOI: 10.1007/s12471-022-01677-9 -
Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines
This study investigates the age and sex-specific risks of myocarditis and pericarditis following Covid-19 mRNA vaccinations, revealing significantly increased risks particularly after the second dose, especially in younger males.
DOI: 10.1038/s41467-022-31401-5 -
Myocarditis in SARS-CoV-2 infection vs. COVID-19 vaccination: A systematic review and meta-analysis
This systematic review and meta-analysis found the risk of myocarditis was more than seven times higher after SARS-CoV-2 infection than after COVID-19 vaccination (pooled RR 15 vs 2), supporting continued use of mRNA COVID-19 vaccines.
DOI: 10.3389/fcvm.2022.951314 -
Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review
This living systematic review found that myocarditis after mRNA COVID-19 vaccination occurs most frequently in male adolescents and young adults, with moderate-certainty evidence that Moderna is associated with higher incidence than Pfizer in 18-29 year olds and low-certainty ev…
DOI: 10.1136/bmj-2021-069445 -
Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
This study investigates the incidence of thrombocytopenic, thromboembolic, and hemorrhagic events following the second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines in Scotland, finding a borderline increased risk of idiopathic thrombocytopenic purpura (ITP) and cerebral venous…
DOI: 10.1038/s41467-022-32264-6 -
Update on Thromboembolic Events After Vaccination Against COVID-19
This review provides an updated synthesis of the incidence, risk factors, and management of thromboembolic events after COVID-19 vaccination, highlighting that such events are rare overall, with higher risk signals for adenoviral-vector vaccines (VITT, CVST) compared to mRNA vac…
DOI: 10.3390/vaccines13080833 -
COVID-19 vaccination–related cardiovascular complications
This narrative review finds COVID-19 vaccination is associated with rare cardiovascular complications, especially mRNA vaccine myocarditis in young men and adenoviral vaccine VITT/VTE, but myocarditis and thrombosis are more common after SARS-CoV-2 infection and benefits outweig…
DOI: 10.36011/cpp.2023.5.e17 -
Cerebral Venous Sinus Thrombosis following COVID-19 Vaccination: Analysis of 552 Worldwide Cases
This study analyzes 552 worldwide cases of cerebral venous sinus thrombosis (CVST) following COVID-19 vaccination, highlighting its rarity, demographic characteristics, clinical outcomes, and potential underlying mechanisms.
DOI: 10.3390/vaccines10020232